Form Type:  SC 13D
Filing Date:  5/19/2017 
CIK:  0001689813 
Address:  234 CHURCH STREET, SUITE 304 
City, State, Zip:  NEW HAVEN, Connecticut 06510 
Telephone:  203-404-0410 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-0.04 (-0.12%)  
Trade Time: 
May 25  
Market Cap: 
Trade BHVN now with 

© 2018  
Description of Business
We are a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Our product candidates are small molecules based on two distinct mechanistic platforms--calcitonin gene-related peptide ("CGRP"), receptor antagonists and glutamate modulators--which we believe have the potential to significantly alter existing treatment approaches across a diverse set of neurologic indications with high unmet need in both large markets and orphan indications. The most advanced product candidate from our CGRP receptor antagonist platform is rimegepant, an orally available, potent and selective small molecule human CGRP receptor antagonist that we are developing for the acute treatment of migraine. We expect to receive the topline results of our two Phase 3 clinical trials in the first quarter of 2018.
Register and access this filing in: